<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077256</url>
  </required_header>
  <id_info>
    <org_study_id>FA002</org_study_id>
    <nct_id>NCT03077256</nct_id>
  </id_info>
  <brief_title>Burst Biologics Foot and Ankle Registry</brief_title>
  <official_title>Multicenter Prospective Registry to Evaluate Use and Outcomes of Burst Biologics Products in Foot and Ankle Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Burst Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smart-Surgical Inc. dba Burst Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective registry was designed as an observational study to ascertain how
      commercially available Burst Products are being used by foot and ankle surgeons performing
      procedures which involve bone grafting, as well as determining relevant patient outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Foot and ankle surgery requiring the use of bone graft is common despite recent advancements
      and improved outcomes with new motion preservation devices (ankle replacement). Autogenous
      bone remains the gold standard but is complicated by donor site morbidity and availability of
      a sufficient volume of graft. Over the past two decades surgeon interest in alternative bone
      grafts has steadily increased. Bone morphogenic proteins, synthetic bone graft substitutes,
      and various allograft products are widely available to surgeons. Limitations on the use of
      allografts in the past were mainly attributed to less than optimal donor screening and
      processing techniques which removed viable components needed to aid in the bone healing
      process.

      In recent years, the focus and scientific advances in various allograft processing techniques
      have allowed the retention of various viable cytokines, growth factors, and cell populations
      which result in enhanced osteogenic and osteoinductive properties. Rigorous donor bone
      screening and meticulous testing has virtually eliminated the risk of disease transmission.

      A unique proprietary cryoprotection processing technique (ProgenokineÂ®) for allograft tissue
      was developed by Smart-Surgical, Inc. and a complete line of allograft products was created
      and is now marketed by Burst Biologics (dba). In addition, rigorous standardized laboratory
      assay techniques and statistical analysis provide consistency and uniformity of the
      biologically active components of Burst allograft products.

      This prospective registry was designed as an observational study to ascertain how
      commercially available Burst Products are being used by foot and ankle surgeons performing
      procedures which involve bone grafting, as well as determining relevant patient outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Fusion (%) Number of fusion patients fused/all fusion patients operated</measure>
    <time_frame>6 Months</time_frame>
    <description>Determined by CT Scan or Plain Radiographs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Consolidation (%) Number of osteotomy patients with bone consolidation/all osteotomy patients operated</measure>
    <time_frame>6 Months</time_frame>
    <description>Determined by CT Scan or Plain Radiographs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in American Orthopedic Foot and Ankle Society Questionnaire (AOFAS) Score</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Foot Function Index Score (FFI)</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Short Form-36 V2</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Foot and Ankle Disorders</condition>
  <condition>Ankle Fusion, Osteotomy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BioBurst Fluid, Burst Allograft</intervention_name>
    <description>BioBurst Fluid, Burst Allograft in Foot and Ankle Surgery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients in the study will be drawn from the individual surgeons practice. Patients
        will be either candidates for foot and ankle surgery after having failed conservative
        treatment or will have had foot and ankle surgery and the surgeon determined that the use
        of a Burst Biologic product is or was clinically indicated. Only patients who consent to
        participate and meet the inclusion-exclusion criteria will be included provided that a
        Burst Biologic product will be used in the surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 18 years or older

          -  Patient diagnosed with a pathology of the hindfoot, foot, or ankle requiring surgical
             intervention.

          -  The surgeon has determined that a Burst Biologic product is or was clinically
             indicated.

          -  Patient capable of understanding the content of the Informed Consent Form.

          -  Patient willing and able to participate in the registry protocol including the
             surgeon's standard follow-up visits and clinical evaluations.

          -  Patient who has agreed to participate in the registry by providing consent per the
             applicable local law and the declaration of Helsinki.

        Exclusion Criteria: The following are relative contraindications for the use of Burst
        Products, however the investigator surgeon is solely responsible for the determination of
        patient eligibility for surgery:

          -  Severe vascular or neurological disease

          -  Uncontrolled diabetes

          -  Severe degenerative disease (other than degenerative disc disease)

          -  Hypercalcemia, abnormal calcium metabolism

          -  Existing acute or chronic infections, especially at the site of the operation

          -  Inflammatory bone disease such as osteomyelitis

          -  Malignant tumors

          -  Patients who are or plan to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Czop, R.Ph.</last_name>
    <role>Study Director</role>
    <affiliation>Medical Affairs Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven M Czop, R.Ph.</last_name>
    <phone>888-322-1191</phone>
    <email>Sczop@smart-surgical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul S Cooper, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Foot and Ankle</name>
      <address>
        <city>Caldwell</city>
        <state>Idaho</state>
        <zip>83605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Burk, DPM</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Smart-Surgical Inc. dba Burst Biologics</investigator_affiliation>
    <investigator_full_name>Burst Biologics</investigator_full_name>
    <investigator_title>Medical Affairs Officer</investigator_title>
  </responsible_party>
  <keyword>Ankle Arthrodesis</keyword>
  <keyword>Cellular Allograft</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

